SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma gets 2 procedural observation from USFDA for Dahej unit

12 Sep 2022 Evaluate

United States Food and Drug Administration (USFDA) has issued Form 483 with 2 procedural observations to Ajanta Pharma’s formulation facility at Dahej in Gujarat. USFDA has conducted inspection at Dahej unit from September 05, 2022 to September 09, 2022. The company is in the process of responding to the same within the stipulated time prescribed by USFDA.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×